Review
Copyright ©The Author(s) 2020.
World J Clin Oncol. May 24, 2020; 11(5): 260-274
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.260
Table 1 Effects of CITED2 in different cancer
Cancer typeCITED2 effectBiological contextCellular effectsInteraction with HIF-1αRef.
Breast cancerOverexpressionCell lines (MCF-7; SKBR-3; MDA-MB-231; MDA-MB-468; NT2.5); primary tumor; mouse xenograftProliferation; migration; metastization; chemoresistance; reduced survivalNot involved[64,65,67-69,71]
Colorectal cancerDownregulationCell lines (RKO; SW480)Migration; invasionNot determined[75]
Prostate cancerOverexpressionCell lines (LNCaP; VCaP; DU145; PC-3; C4-2B; 22RV1); primary tumor; mouse xenograftInvasion; metastizationNot determined[79]
Gastric cancerOverexpressionCell lines (MKN74; MKN28; 7901; AGS; SNU-1; SNU-5; NCI-N87; KATO-III; MNK7; MNK45); primary tumor; transgenic miceProliferation; cell cycle progression; clonogenicity; chemoresistanceNot determined[82,83]
Hepatocellular carcinomaDownregulationCell lines (LO2; Hep3B; HepG2; BEL7404; primary tumorProliferation; clonogenicityNot determined[87-90]
Acute myeloid leukemiaOverexpressionPrimary cell cultures; cell lines (NB4; MOLM-13); transgenic miceCell survival; proliferation; increased quiescence of AML-LSCSelf-renewal of AML-LSC[101,103,104]
Lung cancerUpregulationCell lines (A549; H1975; CL1-0; CL1-5); primary tumorCell cycle progression; clonogenecity; reduced survivalNot determined[110]